AGS67E

DRUG2 trials

Sponsors

Astellas Pharma Global Development, Inc.

Conditions

Acute Myeloid LeukemiaRefractory Lymphoid MalignancyRelapsed Lymphoid Malignancy

Phase 1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

CompletedNCT02175433

Astellas Pharma Global Development, Inc.Refractory Lymphoid Malignancy, Relapsed Lymphoid Malignancy

Start: 2014-10-14End: 2019-10-29Updated: 2024-11-01

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

TerminatedNCT02610062

Astellas Pharma Global Development, Inc.Acute Myeloid Leukemia

Start: 2016-03-29End: 2017-11-21Updated: 2024-11-01

Related Papers

A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies.

Journal of Clinical Oncology2016-05-207 citations